Login to Your Account



Clinic Roundup


Wednesday, September 25, 2013
• Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase II trial, titled “Therapeutic Trial of EPI-743 in Patients with Disorders of Energy Utilization or Oxidation-Reduction.” The crossover study will randomize patients to receive either EPI-743 treatment or placebo for six months before being crossed over to the other arm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription